Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, cross‐over trial
Primary result · iAUC0-8h TG (postprandial hyperlipidaemia)Result — go to the resultDifference −5 % 95% CI −28, +25Authors' conclusion
Inhibition of PCSK9 by alirocumab did not reduce PPL in T2D, confirming that PCSK9 controls remnant cholesterol catabolism rather than intestinal chylomicron production.
Study context
- Population
- Male patients with T2D; age 59 ± 9 years, BMI 32.8 ± 5.5 kg/m², HbA1c 6.7 ± 0.5%cross-over
- Participants
- 14 patients
- Comparison
- Alirocumab 75 mg Q2W vs placebo s/c, 10-week periods, 10-week wash-out
- Primary endpoint
- Percentage reduction in plasma TG response after an oral fat load (iAUC0-8h TG)
Methodological detailsdouble-blind, placebo-controlled, cross-over
- Double-blind
- Placebo-controlled
- Cross-over
Primary result
iAUC0-8h TG (postprandial hyperlipidaemia)
Difference
−5 %
95% CI −28, +25
P = 0.68
Alirocumabvs Placebo
difference −5 % (95% CI −28, +25); P = 0.68
As reported in the abstract
Secondary outcomes
Fasting lipids and apolipoproteins (change with alirocumab)
- Fasting non-HDL cholesterol
- −38.5 ± 5.6%, p = 0.0003
- Remnant cholesterol
- −20.0 ± 13.3%, p = 0.04
- apoB100
- −21.2 ± 6.4%, p = 0.004
- apoE
- −15.3 ± 6.6%, p = 0.02
Postprandial nuclear magnetic resonance (NMR) lipoprotein profiling (change with alirocumab)
- Postprandial VLDL2 cholesterol
- −42% [−55, −25], p < 0.001
- IDL cholesterol
- −26% [−38, −12], p = 0.0007
- No effect on VLDL1 cholesterol or triglyceride (TG) concentrations
Original publication
Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, cross‐over trial. Diabetes Obes Metab. Published 5 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →